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OBJECTIVE: Certain biomarkers suchas theC-reactive protein, serumalbumin, and theneutrophils to lymphocyte ratio are
of prognostic significance regarding survival in different types of cancers. Data from sarcoma patients are sparse and
mainlyderived fromsoft tissuesarcomaand/ormetastatic cases.Adjusting for confounders suchascomorbidity andage is
an essential safeguard against erroneous conclusions regarding the possible prognostic value of these biomarkers. The
aim of this study was to assess the prognostic value of a battery of pretreatment biomarkers in the serum of patients with
localized bone sarcomas and to adjust for potential confounders.MATERIAL ANDMETHODS: All patients diagnosedwith
localized intermediate and high-grade bone sarcoma during 1994 to 2008 were extracted from the Aarhus Sarcoma
Registry. The serum levels of albumin, C-reactive protein, hemoglobin, neutrophils, lymphocytes, and sodium were
collected from the patient records. The prognostic values of overall and disease-specific mortality were tested for each
individual biomarker as well as for the Glasgow prognostic score (GPS) and for a new composite score incorporating five
biomarkers (Aarhus composite biomarker score: ACBS). Adjustmentsweremade for comorbidity aswell as other possible
prognostic factors, such as size, histological type, margin, chemotherapy, and soft tissue extension, using the Cox
proportional hazardmodel.RESULTS:A total of 172 patientswith high- or intermediate-grade localized bone sarcomawere
included. Of these patients, 63 were diagnosed with chondrosarcoma and 109 patients with Ewing/osteosarcoma. The
median agewas 55 years for chondrosarcoma and 19 years for Ewing/osteosarcoma patients. The overall 5-year mortality
was 31% [95%confidence interval (CI): 21-44] and 41% (95%CI: 33-51),whereas the 5-year disease-specificmortalitywas
21% (95%CI: 12-34) and 39% (95%CI: 31-49) for chondrosarcoma and Ewing/osteosarcoma, respectively. Comorbidities
werepresent in12%of theEwing/osteosarcomapatients and in24%of thechondrosarcomapatients.After adjustment for
comorbidity and other confounders, it was found that elevated levels of CRP, low hemoglobin, low sodium, high GPS, and
high ACBS were associated with increased overall mortality. Furthermore, elevated levels of CRP, low hemoglobin, high
GPS, andhighACBSwere associatedwith increaseddisease-specificmortality.CONCLUSION:Elevated levels ofCRP, low
hemoglobin, high GPS, and high ACBS were all independent prognostic factors for both overall and disease-specific
mortality. ACBS is a new three-level score of five biomarkers, but its value has to be confirmed in an independent data set.
Translational Oncology (2016) 9, 322–328t of Experimental Clinical Oncology, Norrebrogade 44, 8000 Aarhus C–DK.
ss article under theCCBY-NC-NDlicense (http://creativecommons.org/licenses/ by-nc-nd/4.0/).
Translational Oncology Vol. 9, No. 4, 2016 Serum Biomarkers in Localized Bone Sarcoma Aggerholm-Pedersen et al. 323Introduction
The prognostic value of different serum biomarkers is well established
in various cancers [1–3]. However, to avoid erroneous conclusions,
adjustments for confounders such as comorbidity and age must be
incorporated into such data analysis.
Very few studies have investigated the prognostic value of serum
biomarkers in sarcoma patients [4], and therefore, little is known
about their prognostic value, especially in bone sarcomas.
Bone sarcoma is a rare group of tumors dominated by
osteosarcoma, Ewing sarcoma, and chondrosarcoma. Ewing sarcoma
and osteosarcoma have similar epidemiological features, both with a
peak incidence rate during the second decade of life [5,6].
Osteosarcoma has a second incidence peak after 60 [7]. Chondro-
sarcoma has a gradual increase in incidence rate up to 75 years of age
[5,6]. Treatment failure is a major problem in clinical practice of bone
sarcomas, and the 5-year survival rate for poor prognosis localized
cases can be as low as 40% [5–7]. Although various prognostic factors
are known, none of them could be used to guide treatment or change
clinical outcome. The search for new and reliable prognostic factors
that can help in allocating patients to the best treatment and improve
the final outcome has to continue.
The aim of this study was to assess the prognostic value of serum
biomarkers taken before the primary treatment of bone sarcoma
adjusted for potential confounders.
A similar study is under preparation for soft tissue sarcomas, but
the results will be reported in a separate study. This is because of the
differences in age distribution, prognosis, treatment modalities, as
well as histopathology between soft tissue and bone sarcomas.
Material and Methods
Study Cohort
All patients diagnosed with Ewing sarcoma, osteosarcoma, or
chondrosarcoma and treated between January 1994 and December
2008 at Aarhus Sarcoma Centre, Denmark, were included in theLocalized, grade 2/3
182
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Figure 1. The number of patients included and excluded from the
Aarhus Sarcoma Registry. The final study population comprises
171 patients.present study. Patients with unclassifiable or low-grade tumors,
metastasis at diagnosis, or no available blood samples were excluded
from the analysis. This resulted in a cohort of 172 patients (Figure 1).
Data Sources
Clinical data were obtained from the newly validated
population-based Aarhus Sarcoma Registry [8], which contains
comprehensive clinical information on each sarcoma patient from
1979 to 2008 in a well-defined geographic area of Denmark. Patients
were diagnosed and treated, according to national guidelines, by an
experienced multidisciplinary sarcoma team.
Biomarkers data were obtained from the clinical laboratory
information system (LABKA) research database, which contains
every blood test taken at any hospital in the northern and central
regions of western Denmark since 2000 [9]. If it was not possible to
obtain the biomarker results from the LABKA research database, the
medical files were reviewed. The LABKA database registers test results
according to the international nomenclature, properties, and units
coding system [10].
The values selected for analysis included a time span from 30 days
prior to sarcoma diagnosis to the day before the first treatment.
Serum albumin, C-reactive protein (CRP), hemoglobin, lympho-
cytes, neutrophils, and sodium were selected for analysis based on
review of literature data. Each biomarker was categorized into normal
or high/low according to the reference value in Aarhus University
hospital at the time. Hypoalbuminemia was defined as albumin levels
b36 g/l or b542 μmol/l. Elevated CRP was defined as values ≥8 mg/l
or ≥75 nmol/l. Low hemoglobin was defined as levels b7.3 mmol/l in
females and b8.3 mmol/l in males. Low sodium was defined as values
b137 mmol/l. Elevated neutrophils to lymphocytes ratio (NLR) was
defined as N5.3. Glasgow prognostic score (GPS) [1,11] was defined
as follows: normal, 1 if either the level of albumin was low or CRP was
high, and 2 if both albumin level was low and the CRP level was high
according to the reference levels stated above. A new biomarker score,
the “Aarhus composite biomarker score” (ACBS) based on albumin,
CRP, neutrophils, lymphocytes, and hemoglobin, was investigated. A
score of 0 means that all serum biomarkers were within the normal
range. A score of 1 means that only one biomarker was abnormal, and
a score of 2 was obtained if more than one abnormal blood test was
observed.
The National Patient Registry [12] was used to obtain data on
comorbidities. All discharge diagnoses from 1 January 1977 until the
date of sarcoma diagnosis were used. Diagnoses within 30 days and all
cancer diagnoses within 90 days prior to the primary diagnosis of
sarcoma were excluded.
Data Analysis and Statistics
Since 1968, all citizens in Denmark have been assigned a unique
10-digit civil personal registration number, which is used throughout
all the Danish administrative registries and clinical databases. This
allows for unambiguous linking and tracking of all patients. The data
from Aarhus Sarcoma Registry, LABKA, and the National Patient
Registry were therefore linked on an individual level using the civil
personal registration number. The vital status and cause of death were
registered through linkage to the Central Population Registry and
Cause of Death Registry [13].
Patient-, tumor-, and treatment-related variables were reported
according to each biomarker level and compared by using the
chi-squared test. The primary end points were overall and
324 Serum Biomarkers in Localized Bone Sarcoma Aggerholm-Pedersen et al. Translational Oncology Vol. 9, No. 4, 2016disease-specific mortality. Death with sarcoma was regarded as a
disease-specific event. The study period ended in 9 October 2013,
and patients alive at this date were censored. The 5-year overall or
disease-specific mortalities were reported by cumulative incidence
functions for NLR, GPS, and ACBS using the Fine and Gray
competing risk model [14]. Crude and adjusted analyses were
performed by using the Cox proportional hazard model. The
following variables were included in the adjusted analysis: age,
comorbidity, size of the primary tumor, histological type, margin,
grade, and soft tissue extension. Tumor size was included as a
continuous variable; all others were analyzed as categorical variables as
follows: age (≤40 vs N40), comorbidity (yes versus no), histological
type (Ewing/osteosarcoma versus chondrosarcoma vs. others), margin
(wide versus nonwide), grade (grade 2 versus grade 3), and soft tissue
extension (yes versus no).
To evaluate the value of the ACBS, we have tested the Cox
proportional hazard model with the ACBS against the model without
the ACBS using likelihood-ratio test.
As a way of comparison between the three different scores (ACBS,
GPS, and NLR), we have used the Akaike information criterion (AIC).
The bootstrapping method with 1000 iterations was used as a form
of validation of the ACBS score.
For all statistical tests, a two-sided P value less than .05 was
regarded as significant. All statistical analyses were performed by using
Stata version 14.Table 1. Patients Characteristic. All Grade 2 and 3 Localized Bone Sarcoma Patient Divided Into
Different Histological Tyypes (n=172)
Total Ewing/Osteosarcoma Chondrosarcoma P Value
Number 109 63
Age (years)
Median (range) 28(2-83) 19(2-75) 55(16-83)
Sex
Female 74(43) 48(44) 26(41)
Male 98(57) 61(56) 37(59) .72
Comorbidity
No 144(84) 96(88) 48(76)
Mild 12(7) 4(4) 8(13)
Moderate/severe 16(9) 9(8) 7(11) .06
Tumor size (cm)
Median (range) 9(2-30) 9(2-21) 9(3-30)
Soft tissue extension
No 29(17) 16(15) 13(20)
Yes 143(83) 97(85) 50(79) .32
Malignancy grade
2 44(26) 1(1) 43(68)
3 128(74) 108(95) 20(32) b .0001
Treatment
Surgery 68(40) 12(11) 56(89)
Surgery + Rt 2(1) 0 2(3)
Surgery + Ch 73(42) 71(65) 2(2)
Surgery + Ch + Rt 19(11) 19(17) 0
Ch 2(1) 2(2) 0
Ch + Rt 4(2) 4(4) 0
No treatment 4(2) 1(1) 3(5) b .0001
Margin
Wide/radical 123(72) 85(78) 38(60)
Intralesional/marginal 39(23) 17(16) 22(35) .014
Recurrent disease
No 130(60) 63(58) 40(63)
Yes 69(40) 46(42) 23(37) .46
Local 24(35) 10(22) 14(61)
Lung 23(33) 20(43) 3(13)
Distant 22(32) 16(35) 6(26) .003
Abbreviations: Rt, radiotherapy; Ch, chemotherapy.
Eight missing values.Ethics
The Ethics Committee of Denmark (1-10-72-233-12) and the
Danish Agency of Data Protection (1-16-02-169-12) approved the
study.
Results
Patients, Tumor, and Treatment Characteristics
A total of 172 patients with localized bone sarcoma were included
in this analysis including 63 patients with chondrosarcoma and 109
with Ewing/osteosarcoma. The median age was 55 years for
chondrosarcoma patients and 19 years for Ewing/osteosarcoma
patients. Comorbidities were present in 12% of the Ewing/
osteosarcoma patients and 24% of the chondrosarcoma patients.
The primary tumors were located in the lower extremities (n = 77),
upper extremities (n = 30), trunk wall including pelvis (n = 48), and
head (n = 17). Patient characteristics are shown in Table 1. The
median follow-up was 8.8 years (range, 4.3 to 19 years) for patients
alive at the end of follow-up. Patient characteristics according to the
biomarkers are seen in Table 2.
Overall and Disease-Specific Mortality
At the end of the follow-up period, 76 patients had died (25
patients with chondrosarcoma and 51 patients with Ewing/
osteosarcoma), yielding a 5-year overall mortality of 31% [95%
confidence interval (CI): 21-44] and 41% (95% CI: 33-51) for
chondrosarcoma and Ewing/osteosarcoma, respectively.
Of the patients who died in the chondrosarcoma group, 16 patients
(64%) died from sarcoma and 9 (36%) died from other causes. Of the
patients who died in the Ewing/osteosarcoma group, 46 patients (90%)
died from sarcoma and 5 (10%) died from other causes. The 5-year
disease-specific mortality was 21% (95% CI: 12-34) and 39% (95%
CI: 31-49) for chondrosarcoma and Ewing/osteosarcoma, respectively.
Prognostic Value of Individual Biomarkers
Crude univariate analysis of individual biomarkers showed that
CRP, serum sodium, and hemoglobin were significant prognostic
factors for overall survival, whereas only CRP and hemoglobin were
significant for disease-specific survival. Adjusting for other known
prognostic factors and confounders such as age, size of the primary
tumor, histological type, margin, soft tissue extension, as well as
comorbidity did not change any of these results. The crude and
adjusted results are illustrated in Table 3.
Prognostic Value of Composite Biomarkers
Crude analysis for the composite biomarkers (NLR, GPS, and
ACBS) showed GPS and ACBS to be significant prognostic scores for
both survival and disease-specific survival. Adjusting for the
previously mentioned confounders including comorbidity did not
affect these results. A significant difference was found between normal
GPS and GPS = 1 (P = .001) but not between normal GPS and GPS =
2 (P = .061). Only five patients had GPS score of 2.
On the other hand, ACBS divided the patients into three
prognostic groups with a reasonable number of patients in each
group (See Table 4). There was a clear trend of increased 5-year
overall mortality with increasing ASBC, from 15% (95% CI: 9-23) in
patients with score of 0 to 47% (95% CI: 32-65) in patients with
score of 1 and to 61% (95% CI: 46-77) in patients with score of 2.
The adjusted cumulative overall mortality and disease-specific
mortality for the various scores are shown in Figure 2. To estimate
Table 2. Patient Characteristics by Biomarkers (N = 172)
Albumin Level (a) CRP Level (b) Hemoglobin Level (c) Neutrophil Level (d) Lymphocyte Level (e) Sodium Level (f) NLR (g) GPS (h)
N (%) Normal Low P
Value
Normal High P
Value
Normal Low P
Value
Normal High P
Value
Normal Low P
Value
Normal Low P
Value
Normal high P
Value
0 1 2 P
Value
Age (years)
0-17 48(28) 41(26) 7(50) 29(27) 15(38) 33(24) 15(41) 37(25) 10(59) 43(32) 4(14) 45(28) 3(27) 44(29) 3(27) 27(26) 14(36) 3(60)
18-40 57(33) 54(34) 3(21) 35(33) 11(27) 48(36) 9(24) 48(33) 5(29) 42(31) 11(38) 54(34) 3(37) 47(31) 6(55) 35(34) 9(23) 2(40)
40+ 67(39) 63(40) 4(29) .16 42(40) 14(35) .49 54(40) 13(35) .14 61(42) 2(12) .01 49(37) 14(48) .14 62(39) 5(45) .88 61(40) 2(18) .22 40(39) 16(41) 0 .23
Sex
Female 74(43) 66(42) 8(57) 46(43) 19(48) 61(45) 13(35) 59(40) 10(59) 59(44) 10(34) 68(42) 6(54) 64(42) 5(45) 44(43) 18(46) 3(60)
Male 98(57) 92(58) 6(43) .27 60(57) 21(52) .66 74(55) 24(65) .27 87(60) 7(41) .15 75(56) 19(66) .35 93(58) 5(45) .43 88(58) 6(55) .83 58(57) 21(54) 2(40) .74
Year of diagnosis
1994-2000 63(36) 57(36) 6(42) 31(29) 11(28) 47(35) 16(43) 54(37) 5(29) 47(35) 12(41) 61(38) 2(18) 56(37) 3(27) 29(28) 12(31) 1(20)
2001-2008 109(63) 101(63) 8(57) .61 75(71) 29(72) .84 88(65) 21(57) .35 92(63) 12(71) .54 87(65) 17(58) .52 100(62) 9(82) .19 96(63) 8(73) .52 73(72) 27(69) 4(80) .87
Comorbidity
No 144(83) 133(84) 11(79) 90(85) 34(85) 117(87) 27(73) 123(84) 15(88) 118(88) 20(69) 136(84) 8(73) 131(86) 7(64) 87(85) 32(82) 5(100)
Mild 12(7) 11(7) 1(7) 10(9) 2(5) 10(7) 2(5) 10(7) 1(6) 6(4) 5(17) 12(7) 0 7(5) 4(36) 9(9) 3(8) 0
Moderate/severe 16(9) 14(9) 2(14) .8 6(6) 4(10) .47 8(6) 8(22) .01 13(9) 1(6) .9 10(7) 4(14) .02 13(8) 3(27) .08 14(9) 0 b .01 6(6) 4(10) 0 .78
Histological type
Ewing/
Osteosarcoma
109(63) 98(62) 11(79) 63(59) 27(68) 83(61) 26(70) 91(62) 15(88) 91(68) 15(52) 103(64) 6(55) 98(64) 8(73) 60(59) 25(64) 5(100)
Chondrosarcoma 63(36) 60(38) 3(21) .22 43(41) 13(32) .37 52(39) 11(30) .33 55(38) 2(12) .03 43(32) 14(48) .1 58(36) 5(45) .53 54(35) 3(27) .58 42(41) 14(36) 0 .17
Tumor size (cm)*
≤5≤5 38(22) 36(23) 2(14) 22(21) 6(15) 32(24) 6(16) 31(21) 3(17) 26(19) 8(28) 35(22) 3(27) 31(20) 3(27) 22(22) 5(13) 1(20)
N5 134(78) 122(77) 12(86) .46 84(79) 34(85) .43 103(76) 31(84) .33 115(79) 14(82) .73 108(81) 21(72) .33 126(78) 10(73) .67 121(80) 8(73) .59 80(78) 34(87) 4(80) .5
Soft tissue
involvement
No 29(17) 28(18) 1(7) 18(17) 4(10) 24(18) 5(14) 29(20) 0 21(16) 8(28) 28(17) 1(9) 28(18) 1(9) 18(18) 4(10) 0
Yes 143(83) 130(82) 13(93) .31 88(83) 36(90) .29 111(82) 32(86) .54 117(80) 17(100) .04 113(84) 21(72) .13 133(82) 10(92) .48 124(82) 10(91) .44 84(82) 35(90) 5(100) .35
Malignancy grade
2 44(26) 41(26) 3(21) 34(32) 5(13) 39(28) 5(14) 38(26) 1(6) 31(23) 8(28) 41(25) 3(27) 37(24) 2(18) 33(32) 6(15) 0
3 128(74) 117(74) 11(79) .71 72(68) 35(73) .02 96(71) 32(86) .06 108(74) 16(94) .07 103(77) 21(72) .61 120(75) 9(72) .89 115(76) 9(82) .64 69(68) 33(85) 5(100) .05
Treatment
Surgery 68(39) 66(42) 2(14) 45(42) 14(35) 56(41) 12(32) 62(42) 1(6) 47(35) 16(55) 64(40) 4(36) 61(40) 2(18) 44(43) 15(38) 1(13)
Surgery+Rt 2(1) 2(1) 0(0) 2(2) 0 2(1) 0 2(1) 0 1(1) 1(3) 2(1) 0 1(1) 1(9) 2(2) 0 1(13)
Surgery+Ch 73(42) 68(43) 5(36) 45(42) 16(40) 58(43) 15(41) 62(42) 8(47) 61(46) 9(31) 69(43) 4(36) 65(43) 5(45) 44(43) 14(36) 3(37)
Surgery+Ch+Rt 19(11) 15(9) 4(29) 9(8) 7(17) 12(9) 7(19) 15(10) 4(24) 17(13) 2(7) 17(11) 2(18) 17(11) 2(18) 8(8) 6(15) 2(25)
Ch 2(1) 2(1) 0(0) 0 2(5) 0 2(5) 0 2(12) 2(1) 0 2(1) 0 2(1) 0 0 2(5) 1(13)
Ch+Rt 4(2) 2(1) 2(14) 3(3) 0 4(3) 0 3(2) 1(6) 4(3) 0 4(2) 0 4(3) 0 2(2) 1(3) 0
No treatment 4(2) 3(2) 1(7) .01 2(2) 1(3) .13 3(2) 1(3) .06 2(1) 1(6) b .01 2(1) 1(3) .27 3(2) 1(9) .74 2(1) 1(9) .08 2(2) 1(3) 0 .24
Margin
Wide/radical 123(71) 115(72) 8(57) 75(71) 30(75) 99(73) 24(65) 110(75) 9(53) 94(70) 25(86) 116(72) 7(63) 111(73) 8(63) 73(72) 28(72) 4(80)
Intralesinal/
marginal
39(23) 36(23) 3(21) .03 26(25) 7(88) .56 29(21) 10(27) .57 31(21) 4(24) b .01 32(24) 3(10) .21 36(22) 3(27) .81 33(21) 2(18) .85 25(25) 7(18) 1(20) .57
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Table 3. Crude and Adjusted Analysis (N = 172)
Overall Mortality Disease-Specific Mortality
HR (95% CI) HR (95% CI)
No. Events Crude Adjusted Events Crude Adjusted
Albumin
Normal 158 68 1 1 55 1 1
Low 14 8 1.9(0.9-3.9) 2.8(0.9-4.8) 7 2.1(1.0-4.6) 1.7(0.7-4.1)
CRP
Normal 106 32 1 1 27 1 1
high 40 29 3.6(2.2-6.0) 3.6(2.1-6.3) 24 3.5(2.0-6.1) 3.6(2.0-6.5)
Missing 26 15 11
Hemoglobin
Normal 135 51 1 1 43 1 1
Low 37 25 2.3(1.4-3.8) 1.9(1.1-3.1) 19 2.2(1.3-3.7) 1.8(1.0-3.2)
Sodium
Normal 161 69 1 1 57 1 1
Low 11 7 2.3(1.0-5.0) 2.6(1.2-5.8) 5 2.0(0.8-4.9) 2.1(0.8-5.2)
Lymphocytes
Normal 134 56 1 1 46 1 1
Low 29 17 1.6(0.9-2.7) 1.6(0.9-2.9) 14 1.6(0.9-2.8) 1.8(1.0-3.6)
Missing 9 3 2
Neutrophils
Normal 146 63 1 1 51 1 1
High 17 10 1.8(0.9-3.5) 2.0(1.0-4.2) 9 2.0(1.0-4.0) 1.8(0.8-3.9)
Missing 9 3 2
NLR
Normal 152 66 1 1 54 1 1
High 11 7 2.0(0.9-4.4) 2.2(1.0-5.2) 6 2.1(0.9-5) 2.3(0.9-5.5)
Missing 9 3 2
GPS
Normal 102 30 1 1 25 1 1
1 39 28 3.6(2.0-6.1) 3.2(1.9-5.6) 23 3.6(2.0-6.4) 3.2(1.8-5.7)
2 5 3 3.7(1.1-12) 4.6(1.3-16) 3 4.2(1.3-14) 4.3(1.2-15)
Missing 26 15 11
ACBS
Score = 0 73 18 1 1 15 1 1
Score = 1 34 17 2.5(1.3-5) 2.8(1.4-5.7) 15 2.7(1.3-5.6) 2.7(1.3-5.6)
Score = 2 36 26 4.4(2.4-8) 3.6(1.9-6.9) 21 4.2(2.2-8.2) 3.6(1.8-7.2)
Missing 29 15 11
Adjustment were made for age, comorbidity, size, grade, histological type, margin, and soft tissue extension.
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NLR, and ASBC) were compared using AIC. The least favorable
prognostic score was the NLR with AIC = 568, whereas the GPS and
ASBC had similar weights with AIC of 458 and 457, respectively.
As validating the results in another data set is not currently feasible,
we resorted to examining the ASBC using bootstrapping test with
1000 iterations. The test confirmed the value of the score as an
independent prognostic factor with a hazard rate of 2.66 (95% CI:
1.08-6.45) for score of 1 and 3.59 (95% CI: 1.31-7.86) for score of 2.
Discussion
The use of various serum biomarkers in determining the prognosis for
different types of cancer has been widely investigated [15–18]. Most
of these tested biomarkers are related to systemic inflammatory
process of a sort. This is not surprising because it is now known that
systemic inflammation can be associated with cancer developmentTable 4. The Distribution of Patients According to the GSP and ACBS Scores
GPS
ACBS 0 1 2 Total
0 73 0 0 73
1 21 13 0 34
2 5 26 5 36
Total 99 39 5and progression [19]. The biochemical markers of inflammation
include elevated CRP, hypoalbuminemia, and increased leukocytes
and/or neutrophils. Many studies have pointed to the role of these
various systemic inflammation-based prognostic biomarkers in different
cancers. This also included the increase in theNLR [2,20]. To refine the
prognostic value of these serum biomarkers, different biomarker scores
have been developed [3,11,20]. The most commonly used are the
Glasgow score and NLR. However, these factors are unspecific. It is
known that NLR values increase in acute pancreatitis [21], cardiac
events [22], atherosclerosis, abnormal thyroid function, and old age.
Moreover, different drugs such as angiotensin-converting enzyme
inhibitors, angiotensin blockers, and statins [23] are able to affect the
NLR. This underlines the importance of correcting for comorbidities.
Most studies on the role of biomarkers in the prognosis of sarcoma
have been made for soft tissue sarcomas. In bone sarcomas, CRP,
albumin level [24,25], and lymphocyte and/or neutrophils [26,27]
were shown to be of prognostic value. These few studies, however,
suffer from different problems such as not correcting for confounders
and the lack of pretreatment values or hazard ratio levels.
In the present study, we have investigated albumin, CRP,
hemoglobin, neutrophils, lymphocytes, and sodium separately. We
also tested scores such as GPS and NLR that include more than one
variable. In addition, we are presenting a new composite biomarker
score named “ACBS” that combines and includes all the biomarkers
tested in this study.
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Figure 2. The cumulative incidence of overall and disease-specific mortality by GPS (n = 146), NLR (n = 163), and ACBS (n = 143).
Biomarker score = 0: normal value for all investigated biomarkers. Biomarker score = 1: one abnormal marker. Biomarker score = 2:
more than one abnormal biomarker. The analyses were performed using Fine and Gray competing risk model.
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chondrosarcoma separately because of the low number of events in
some of the biomarkers tested; therefore, the adjusted analyses were only
performed for the whole group of bone sarcomas. This may be
considered as a weakness, and other studies testing the biomarker scores
in a larger material of single histopathological subtype may be needed.
We decided to report both the overall mortality and the
disease-specific mortality because 39 % of the chondrosarcoma
patients died from other causes than sarcoma compared with Ewing/
osteosarcoma where only 10% died from other causes than sarcoma.
The ability to link our patients’ data on individual basis with other
Danish registries including the cause of death registry is unique and
makes disease-specific estimate robust.
CRP is the only single biomarker that according to the literature is
prognostic for both soft tissue [28,29] and bone sarcomas [25]. In the
present study, we found CRP to be prognostic for overall and
disease-specific mortality even when adjusted for confounders such as
the presence of comorbidities and age.
Low levels of hemoglobin were observed in 22% of the patients in
this study and were shown to be an independent prognostic factor for
both disease-specific mortality and overall mortality as shown by
Nakamura et al. [30].
Elevated NLR was recorded in only 11 patients in the present
study, and severe comorbidity as a causative factor could be excluded.
We were not able to retrieve information about medication at the
time of diagnosis, but by adjusting for comorbidity, we believe that
any bias would be minimized.
The GPS score has been shown to be prognostic for survival in
different cancers including lung cancer [11], breast cancer [1],esophagus cancer [31], and kidney cancer [32]. This prognostic score
has not yet been tested in bone sarcoma patients. We found that GPS
was an independent prognostic factor for both overall mortality and
disease-specific mortality when adjusted for different confounders.
The score could not detect a difference in overall or disease-specific
mortality between GPS = 1 and GPS = 2. This might be due to the
low number of patients having a GPS value of 2 in this study.
Why ACBS and is it better than other scores?
The exact inflammatory process or mechanism behind the poor
prognosis of a certain marker or score is not known. We felt therefore
the need for another more comprehensive score that takes into
account all the markers that were shown to be of prognostic value in
our material. We have therefore tested a new biomarker score that
equally weighs and categorizes the number of abnormal biomarker
values taking CRP, albumin, neutrophils, lymphocytes, and
hemoglobin into account (ABCS).
AIC is a measure for comparing maximum likelihood models. It
was used here to compare the three composite scores (NLR, GPS, and
ACBS). The model with the smaller value is considered to be better.
In our analysis, the ACBS performed better than NLR but similar to
GPS.
However, whereas GPS identified only 5 patients as belonging to
the worst prognosis group, ACBS was able to identify 36 patients.
ACBS was thus able to separate the patients into three groups with
reasonably equal number of patients in each group. ASBC was
prognostic for both overall and disease-specific mortality. It also
showed an obvious trend toward poorer prognosis with higher score.
The difference between score 1 and 2 was not significant, which could
be due to the low number of patients.
328 Serum Biomarkers in Localized Bone Sarcoma Aggerholm-Pedersen et al. Translational Oncology Vol. 9, No. 4, 2016As we do not have access to a validation cohort, we decided to test the
robustness of the ACBS score using bootstrapping test with 1000
iterations, and the results confirmed the value of the score as an
independent prognostic factor in patients with localized bone sarcoma.
Despite this confirmation, it is recommended that in order for ACBS to
be incorporated into clinical practice, it has to be tested in a larger
material preferably with one histopathological type.
In conclusion, this study showed that for patients with localized bone
sarcomas, biomarkers such as elevated level of CRP and low hemoglobin
and composite biomarkers scores such as GPS and ACBS are
independent prognostic factors for both overall and disease-specific
mortality. ACBS is a new three-level score of five biomarkers, but its
value has to be confirmed in an independent data set.
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